PJHRX Mutual Fund

PJHRX Mutual Fund

NAV$36.70
See how much of PJHRX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Sep 30, 2026

Net Assets
$5M
Expense Ratio
1.48%
Dividend Yield (Current)
-
Holdings
57
Inception Date
Feb 3, 2012
Fund Family
PGIM Investments
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+11.56%
1 Year+19.01%
3 Year+16.76%
5 Year+7.16%
10 Year+12.78%

Asset Allocation

Stocks: 96.60%
Cash: 3.40%
See how much of PJHRX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co17.76%
MRKMerck & Company Inc7.25%
TMOThermo Fisher5.56%
UNHUnitedhealth Group Incorporated5.53%
VRTXVertex Pharmaceuticals Inc4.19%
Top 10 Concentration: 56.44%Report Date: Sep 30, 2026
Download all 57 holdings for PJHRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$14.03
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

PJHRX Mutual Fund Overview

PJHRX Mutual Fund (PGIM Jennison Health Sciences Fund Class R) is managed by PGIM Investments with $5.3M in net assets. PJHRX expense ratio is 1.48%, holding 57 positions across sectors including Health Care, Financials, Information Technology. Inception date: 2012-02-03.

PJHRX performance shows a YTD return of 11.56%. The 1-year return is 19.01% and the 5-year return is 7.16%.

PJHRX top holdings include Eli Lilly & Co (17.8%), Merck & Company Inc (7.3%), Thermo Fisher (5.6%), Unitedhealth Group Incorporated (5.5%), Vertex Pharmaceuticals Inc (4.2%). Go to all PJHRX holdings, PJHRX sectors, or PJHRX dividends.

PJHRX can be compared against other funds. Use PJHRX overlap to find shared positions, or PJHRX vs another fund for a side-by-side view. PJHRX alternatives are available via the screener, along with tax-loss harvesting opportunities.